Clinical Trials Logo

Intracerebral Haemorrhage clinical trials

View clinical trials related to Intracerebral Haemorrhage.

Filter by:

NCT ID: NCT01947361 Active, not recruiting - Stroke Clinical Trials

Heart Rate and Initial Presentation of Cardiovascular Diseases (Caliber)

Start date: January 2012
Phase: N/A
Study type: Observational

Study of heterogeneity in associations between heart rate and the initial presentation of 12 cardiovascular diseases.

NCT ID: NCT01937065 Active, not recruiting - Stroke Clinical Trials

Social Deprivation and Initial Presentation of 12 Cardiovascular Diseases: a CALIBER Study

IP4
Start date: January 2012
Phase: N/A
Study type: Observational

Study of heterogeneity in associations between social deprivation and the initial presentation of 12 cardiovascular diseases.

NCT ID: NCT01702636 Completed - Stroke Clinical Trials

STOP-AUST: The Spot Sign and Tranexamic Acid On Preventing ICH Growth - AUStralasia Trial

STOP-AUST
Start date: December 2012
Phase: Phase 2
Study type: Interventional

The aim of the study is to test if intracerebral haemorrhage (ICH) patients who have contrast extravasation on computed tomography angiography, the "spot sign", have lower rates of haematoma growth when treated with tranexamic acid within 4.5 hours of stroke onset, compared to placebo.

NCT ID: NCT01566786 Completed - Clinical trials for Acquired Bleeding Disorder

Safety and Preliminary Efficacy of Activated Recombinant Human Factor VII in Acute Intracerebral Haemorrhage

Start date: August 2001
Phase: Phase 2
Study type: Interventional

This trial is conducted in Asia, Europe and Oceania. The aim of this trial is to evaluate the safety and preliminary efficacy of activated recombinant human factor VII (NovoSeven®) in preventing early haematoma growth in acute Intracerebral Haemorrhage (ICH).

NCT ID: NCT01563445 Completed - Clinical trials for Acquired Bleeding Disorder

Safety and Preliminary Efficacy of Activated Recombinant Human Factor VII for Preventing Early Hematoma Growth in Acute Intracerebral Haemorrhage

Start date: November 2001
Phase: Phase 2
Study type: Interventional

This trial is conducted in the United States of America (USA). The aim of this trial is to evaluate the safety and preliminary efficacy of activated recombinant human factor VII (NovoSeven®) for preventing early hematoma growth in acute Intracerebral Hemorrhage (ICH).

NCT ID: NCT01320423 Active, not recruiting - Clinical trials for Intracerebral Haemorrhage

Surgical Trial in Lobar Intracerebral Haemorrhage

Start date: August 2010
Phase: N/A
Study type: Interventional

To establish whether a policy of earlier surgical evacuation of the haematoma in selected patients with spontaneous lobar ICH will improve outcome compared to a policy of initial conservative treatment. The trial will also help to better define the indications for early surgery. This will overcome two of the criticisms of STICH (timing was too late and sometimes location was too deep). The subgroup identified in STICH is clinically sensible and the hypothesis identified for STICH II is in line with current neurosurgical opinion.

NCT ID: NCT00426803 Completed - Clinical trials for Acquired Bleeding Disorder

Recombinant Factor VIIa in Acute Intracerebral Haemorrhage

Start date: August 2002
Phase: Phase 2
Study type: Interventional

This trial is conducted in North America, Europe, Asia and Oceania. The purpose of this study is to evaluate safety and efficacy of Recombinant Factor VIIa in patients with acute intracerebral bleeding.

NCT ID: NCT00266006 Completed - Clinical trials for Acquired Bleeding Disorder

Factor VIIa in Acute Intracerebral Haemorrhage

Start date: January 2006
Phase: Phase 2
Study type: Interventional

This trial is conducted in Japan. The purpose of this trial is to evaluate the safety and preliminary efficacy of Activated Recombinant Factor VII (NN-007) in patients with acute intracerebral haemorrhage.

NCT ID: NCT00127283 Completed - Clinical trials for Acquired Bleeding Disorder

Recombinant Factor VIIa in Acute Intracerebral Haemorrhage

FAST
Start date: May 2005
Phase: Phase 3
Study type: Interventional

This trial is conducted in Asia, Europe, Middle East, North America, Oceania, and South America. The purpose of this study is to evaluate the treatment of Recombinant Factor VIIa (eptacog alfa (activated)) in patients with acute intracerebral bleeding. It is expected that more patients will recover without severe permanent disability after acute treatment with Recombinant Factor VIIa by reducing further intracerebral bleeding.